Ambeed.cn

首页 / / / / Pranlukast

普鲁司特 /Pranlukast {[allProObj[0].p_purity_real_show]}

货号:A108288 同义名: 普仑司特 / ONO-1078;ONO-RS-411 Ambeed 开学季,买赠积分,赢豪礼

Pranlukast 是一种选择性的 CysLT1 受体拮抗剂,对 CysLT1 受体具有高亲和力,IC50 值为 0.5 nM。Pranlukast 具有抗过敏和抗哮喘作用,可用于过敏性疾病和哮喘的研究。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Pranlukast 化学结构 CAS号:103177-37-3
Pranlukast 化学结构
CAS号:103177-37-3
Pranlukast 3D分子结构
CAS号:103177-37-3
Pranlukast 化学结构 CAS号:103177-37-3
Pranlukast 3D分子结构 CAS号:103177-37-3
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Pranlukast 纯度/质量文件 产品仅供科研

货号:A108288 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

JACS Au, 2024. Ambeed. [ A148168 ]
JMC, 2024. Ambeed. [ A187643 ]
JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]
Biomacromolecules, 2024. Ambeed. [ A110759 ]
Biomacromolecules, 2024. Ambeed. [ A203543 ]
更多 >
产品名称 LTR 其他靶点 纯度
Montelukast Sodium {[allProObj[0].p_purity_real_show]}
MK571 {[allProObj[0].p_purity_real_show]}
Zafirlukast {[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Pranlukast 生物活性

描述 Pranlukast is a selective, competitive antagonist of the cysteinyl leukotrienes, leukotriene (LT) C4, LTD4 and LTE4, antagonising binding at the cysteinyl leukotriene type 1 (CysLT1) receptor. In isolated human bronchial smooth muscle preparations, pranlukast caused a concentrationdependent inhibition or reversal of LTC4-, LTD4- and house dust antigen-induced bronchial contraction, but had minimal or no effect on histamine (H)- prostaglandin F2α-, acetylcholine- or thromboxane, A2 (TXA2) mimetic agonist-induced contraction (at 37°C)[3]. In vitro , antigen-induced contraction was inhibited more effectively with pranlukast than with an H1-receptor antagonist; however, pranlukast in combination with an H1-receptor antagonist was more potent than either agent alone[4].Pranlukast has shown a range of anti-inflammatory effects on airways in animal models, including attenuation or inhibition of microvascular leakage in the trachea, bronchi and small airways,LTD4-, capsaicin- or allergen-induced eosinophilia in bronchoalveolar lavage fluid (BAL), bronchial epithelial and subepithelial tissue or lung parenchyma and the expression of mRNA for interleukin-5 in BAL cells[5]. In addition, pranlukast inhibited airway smooth muscle DNA synthesis and reduced allergen-induced airway smooth muscle cell thickness in repeatedly ovalbumin-sensitised rats[6].Animal models show that pranlukast is cleared through metabolic transformation (primarily glucuronic acid conjugation); an in vitro study indicated that the drug is metabolised via cytochrome P450 (CYP) enzymes. The main metabolites formed are mono- and dihydroxylated molecules and their glucuronide conjugates[7].

Pranlukast 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00127647 Rhinitis, Allergic, Seasonal Phase 3 Completed - -
NCT01539304 Perennial Allergic Rhinitis Phase 3 Completed - Korea, Republic of ... 展开 >> Seoul National University Hodpital Seoul, Korea, Republic of 收起 <<
NCT00410735 Chronic Sinusitis Phase 3 Completed - Japan ... 展开 >> Chubu region Chubu, Japan Hokuriku region Hokuriku, Japan Kanto region Kanto, Japan Kinki region Kinki, Japan Kyushu region Kyushu, Japan Tohoku region Tohoku, Japan 收起 <<

Pranlukast 参考文献

[1]Ichiyama T, Hasegawa S, et al. Pranlukast inhibits NF-kappa B activation in human monocytes/macrophages and T cells. Clin Exp Allergy. 2003 Jun;33(6):802-7.

[2]Liu YC, Khawaja AM, et al. Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitro. Br J Pharmacol. 1998 Jun;124(3):563-71.

[3] Susan J Keam,et al. Pranlukast: a review of its use in the management of asthma. Drugs. 2003;63(10):991-1019.

[4]Yamaguchi T,et al. A novel leukotriene antagonist, ONO-1078, inhibits and reverses human bronchial contraction induced by leukotrienes C4 and D4 and antigen in vitro . Am Rev Respir Dis 1992 Oct; 146 (4): 923-9.

[5]Hojo M,et al. Role of cysteinyl leukotrienes in CD4+ T cell-driven late allergic airway responses.J Pharmacol Exp Ther 2000 May; 293 (2): 410-6

[6]Salmon M,et al. Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats. Br J Pharmacol 1999 Jul; 127 (5): 1151-8

[7]The Japan Pharmaceutical Manufacturers Association. Japan Pharmaceutical Reference: Onon capsules [online].

Pranlukast 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.08mL

0.42mL

0.21mL

10.38mL

2.08mL

1.04mL

20.77mL

4.15mL

2.08mL

Pranlukast 技术信息

CAS号103177-37-3
分子式C27H23N5O4
分子量 481.503
别名 普仑司特 ;ONO-1078;ONO-RS-411;SB 205312
运输蓝冰
存储条件

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 35 mg/mL(72.69 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。